NCT00546260

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

Randomized Trial to Evaluate Effect of Adjunctive Antiplatelet Therapy With Intravenous PRT060128, a Selective P2Y12-Receptor Inhibitor, Before Primary Percutaneous Intervention (PCI) in ST-Elevation Myocardial Infarction (STEMI) Patients

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Portola Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)

Detailed description

Patients with STEMI who are to undergo primary PCI will be randomized to an intravenous (iv) bolus of placebo vs. PRT060128 prior to angiography.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	placebo	administration of iv bolus prior to angiography
DRUG	PRT060128 Potassium	administration of iv bolus prior to angiography

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2007-10-18
• Last updated: 2023-08-16
• Results posted: 2011-01-25

Locations

31 sites across 2 countries: United States, Canada